A RANDOMIZED CONTROLLED CLINICAL TRIAL OF CIPROFLOXACIN IN BACTERIAL INFECTIONS

Ciprofloxacin is the most active agent in comparison with other new broad-spec-trum quinolones. A randomized controlled clinical trial on oral ciprofloxacin compared with bothcephalexin and norfloxacin, was conducted. 33 patients were treated with ciprofloxacin 200mg threetimes daily or 400mg twice daily orally for 7-14 dyas. The dosage and therapeutic duration of controlswere as follows: cephalexin 1-2g three times daily for 10-14 days, norfloxacin 200mg three timesdaily or 400mg twice daily for 7-14 days. Ciprofloxacin was compared with cephalexin in 21 respira-tory tract infections, 2 skin and soft tissue infections. 11 patients received ciptofloxacin. 10 werecured or excellent, and 1 failed. Favorable bacteriological responses were seen for 6 of 7 organismswith ciprofloxacin. 10 of 12 were cured, and 2 failed. The bacteriological responses occurred in 7 of9 organisms by cephalexin. Ciprofloxacin was compared with norfloxacin of 20 urinary tract and 24intestinal infections. All of these patients were cured. 40 isolates were obtained and all were cleaned.There was no statistical difference between ciprofloxacin and controls. The overall clinical efficacyrate of ciprofloxacin was 96.97%, and bacterial clearance rate was 96.43%.